#Etavopivat

#NovoNordisk is planning to move ahead with #regulatory filings for #etavopivat, potentially a first-in-class therapy for #sicklecelldisease, based on positive results in a phase 3 trial.

buff.ly/hI6iav7

Investigational Etavopivat Shows Potential in Reducing Sickle Cell Disease Crises Novo Nordisk's phase 2 findings suggest that etavopivat may significantly decrease vaso-occlusive crises in sickle cell patients, marking a promising advance in treatment.

Investigational Etavopivat Shows Potential in Reducing Sickle Cell Disease Crises #USA #Plainsboro #Etavopivat #sicklecell #NovoNordisk